Citadel Advisors’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $27.2K | Buy |
33,625
+33,591
| +98,797% | +$27.2K | ﹤0.01% | 5594 |
|
|
2025
Q1 | $26 | Sell |
34
-10,263
| -100% | -$7.85K | ﹤0.01% | 5857 |
|
|
2024
Q4 | $13.1K | Sell |
10,297
-4,928
| -32% | -$6.28K | ﹤0.01% | 5696 |
|
|
2024
Q3 | $31.5K | Sell |
15,225
-16,163
| -51% | -$33.5K | ﹤0.01% | 5234 |
|
|
2024
Q2 | $120K | Buy |
31,388
+1,593
| +5% | +$6.07K | ﹤0.01% | 4880 |
|
|
2024
Q1 | $141K | Sell |
29,795
-65,535
| -69% | -$311K | ﹤0.01% | 4943 |
|
|
2023
Q4 | $407K | Sell |
95,330
-204,771
| -68% | -$874K | ﹤0.01% | 3942 |
|
|
2023
Q3 | $927K | Buy |
300,101
+263,232
| +714% | +$813K | ﹤0.01% | 3118 |
|
|
2023
Q2 | $166K | Buy |
+36,869
| New | +$166K | ﹤0.01% | 4535 |
|
|
2023
Q1 | – | Sell |
-18,232
| Closed | -$110K | – | 6403 |
|
|
2022
Q4 | $110K | Buy |
18,232
+2,498
| +16% | +$15.1K | ﹤0.01% | 4973 |
|
|
2022
Q3 | $104K | Sell |
15,734
-93,889
| -86% | -$621K | ﹤0.01% | 5099 |
|
|
2022
Q2 | $572K | Buy |
109,623
+58,725
| +115% | +$306K | ﹤0.01% | 3995 |
|
|
2022
Q1 | $352K | Sell |
50,898
-87,602
| -63% | -$606K | ﹤0.01% | 4793 |
|
|
2021
Q4 | $1.73M | Buy |
138,500
+124,005
| +856% | +$1.54M | ﹤0.01% | 3217 |
|
|
2021
Q3 | $453K | Buy |
+14,495
| New | +$453K | ﹤0.01% | 4631 |
|
|
2021
Q2 | – | Sell |
-19,496
| Closed | -$845K | – | 6930 |
|
|
2021
Q1 | $845K | Buy |
+19,496
| New | +$845K | ﹤0.01% | 4085 |
|
|
2020
Q4 | – | Sell |
-110,915
| Closed | -$3.34M | – | 5470 |
|
|
2020
Q3 | $3.34M | Buy |
+110,915
| New | +$3.34M | ﹤0.01% | 1818 |
|